A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Tranexamic Acid (Cyklokapron)

Antifibrinolytic Agent class · 23 generic manufacturers · 25 ANDAs filed at FDA.

First FDA approval1986-12-30
Generic availableYes · 23 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$4.8M in CY2024 Part D spend108K claims · 83K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.348/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.408
Across all dosage forms in distribution.
Highest NADAC
$0.947
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema13 entries indexed · 4 visible
What is Tranexamic Acid used for?

Tranexamic Acid is a Antifibrinolytic Agent medication tracked in Medicare Part D.

Is there a generic for Tranexamic Acid?

Yes. 25 ANDAs filed at FDA, 23 generic manufacturers currently shipping.

How much does my plan pay for Tranexamic Acid?

Across 329 Part D plans, Tranexamic Acid averages $0.408/unit (NADAC). Lowest available: $0.348/unit. Highest in distribution: $0.947/unit.

Is Tranexamic Acid on the FDA shortage list?

No. Tranexamic Acid is not currently on the FDA Drug Shortage Database.

9 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Antifibrinolytic Agent1 alternative in D1
01
Aminocaproic Acid
Antifibrinolytic Agent
$0.765Lowest NADAC
15Generic mfrs
$3.0MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.